In this study, serum GDF-15 levels were measured in patients with PD, as well as in patients with PSP and MSA, to investigate the potential usefulness of serum GDF-15 levels as a biomarker in differential diagnosis. This evidence concerns the gene GDF15 and supranuclear palsy, progressive, 1.